<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl2">
 <label>Table 2</label>
 <caption>
  <p>Zika Vaccines in Development</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Institute/company</th>
    <th>Status</th>
    <th>Vaccine(s) platform(s)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Inovio Pharmaceuticals, Inc</td>
    <td>In phase 1 clinical trials</td>
    <td>DNA vaccine</td>
   </tr>
   <tr>
    <td>NIH</td>
    <td>In phase 1 clinical trials</td>
    <td>DNA vaccine
     <break/>Live VSV recombinant (early R&amp;D)
     <break/>Live attenuated ZIKV (early R&amp;D)
    </td>
   </tr>
   <tr>
    <td>WRAIR/Sanofi Pasteur Limited</td>
    <td>In phase 1 clinical trials</td>
    <td>Whole, purified, inactivated virus</td>
   </tr>
   <tr>
    <td>Butantan Institute</td>
    <td>In phase 1 clinical trials
     <break/>Early-stage research
    </td>
    <td>Live, DENV-vectored vaccine expressing premembrane/membrane and envelope proteins
     <break/>Purified inactivated virus
    </td>
   </tr>
   <tr>
    <td>Bharat Institute of Science and Technology</td>
    <td>Preclinical/animal studies</td>
    <td>Purified inactivated virus
     <break/>VLP-expressing polyprotein
    </td>
   </tr>
   <tr>
    <td>NewLink Genetics Corporation</td>
    <td>Preclinical/animal studies</td>
    <td>Purified inactivated virus</td>
   </tr>
   <tr>
    <td>PaxVax, Inc</td>
    <td>Preclinical/animal studies</td>
    <td>Purified inactivated virus</td>
   </tr>
   <tr>
    <td>Novavax, Inc</td>
    <td>Preclinical/animal studies</td>
    <td>Protein nanoparticle vaccine</td>
   </tr>
   <tr>
    <td>Replikins Ltd</td>
    <td>Preclinical/animal studies</td>
    <td>Synthetic peptide vaccine</td>
   </tr>
   <tr>
    <td>Pharos Biologicals LLC</td>
    <td>Preclinical/animal studies</td>
    <td>DNA vaccine</td>
   </tr>
   <tr>
    <td>Bio-Manguinhos</td>
    <td>Early-stage research</td>
    <td>Purified inactivated virus
     <break/>YF17DD chimera
     <break/>VLP
     <break/>DNA
    </td>
   </tr>
   <tr>
    <td>US CDC</td>
    <td>Early-stage research</td>
    <td>VLP expressing ZIKV DNA
     <break/>Live adenovirus recombinant
    </td>
   </tr>
   <tr>
    <td>CureVac AG</td>
    <td>Early-stage research</td>
    <td>Thermostabile mRNA-based vaccine</td>
   </tr>
   <tr>
    <td>Geovax Labs, Inc</td>
    <td>Early-stage research</td>
    <td>Live MVA recombinant</td>
   </tr>
   <tr>
    <td>GlaxoSmithKline plc</td>
    <td>Early-stage research</td>
    <td>Self-amplifying mRNA platform
     <break/>Whole, inactivated virus
    </td>
   </tr>
   <tr>
    <td>Hawaii Biotech Inc</td>
    <td>Early-stage research</td>
    <td>Aluminium hydroxide gel (Alhydrogel) + recombinant protein</td>
   </tr>
   <tr>
    <td>University of Oxford</td>
    <td>Early-stage research</td>
    <td>Live adenovirus recombinant</td>
   </tr>
   <tr>
    <td>Protein Sciences Corporation</td>
    <td>Early-stage research</td>
    <td>Recombinant envelope protein</td>
   </tr>
   <tr>
    <td>Sanofi</td>
    <td>Early-stage research</td>
    <td>YF17D chimera</td>
   </tr>
   <tr>
    <td>Sementis</td>
    <td>Early-stage research</td>
    <td>Live poxvirus recombinant</td>
   </tr>
   <tr>
    <td>Themis Bioscience GmbH</td>
    <td>Early-stage research</td>
    <td>Live measles recombinant</td>
   </tr>
   <tr>
    <td>Valneva SE</td>
    <td>Early-stage research</td>
    <td>Purified inactivated virus</td>
   </tr>
   <tr>
    <td>Mayo Clinic Vaccine Research Group</td>
    <td>Early-stage research</td>
    <td>Naturally processed and HLA-presented ZIKV peptides packaged with biodegradable nanoparticles</td>
   </tr>
   <tr>
    <td>Moderna, Inc</td>
    <td>Early-stage research</td>
    <td>Lipid nanoparticle–delivered mRNA</td>
   </tr>
   <tr>
    <td>Emergent BioSolutions Inc</td>
    <td>Early-stage research</td>
    <td>Inactivated, whole virus</td>
   </tr>
   <tr>
    <td>Institut Pasteur of Shanghai</td>
    <td>Early-stage research</td>
    <td>Recombinant subunit VLP</td>
   </tr>
   <tr>
    <td>Takeda Pharmaceutical Company Limited</td>
    <td>Early-stage research</td>
    <td>Alum adjuvanted, inactivated whole virus</td>
   </tr>
   <tr>
    <td>Edward Jenner Institute for Vaccine Research</td>
    <td>Early-stage research</td>
    <td>Simian adenovirus vector</td>
   </tr>
   <tr>
    <td>VBI Vaccines Inc</td>
    <td>Early-stage research</td>
    <td>VLP containing envelope and NS1 proteins</td>
   </tr>
   <tr>
    <td>Vaxart, Inc</td>
    <td>Early-stage research</td>
    <td>Recombinant oral vaccine</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>CDC = Centers for Disease Control and Prevention; DENV= dengue virus; mRNA = messenger RNA; MVA = modified vaccinia virus ankara; NIH = National Institutes of Health; R&amp;D = research and development; VLP = virus-like particles; VSV= vesicular stomatitis virus; WRAIR = Walter Reed Army Institute of Research; ZIKV = Zika virus.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
